-

Concert Pharmaceuticals to Present at Upcoming Investor Conferences

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will participate at the following upcoming virtual investor conferences:

  • The Jefferies Virtual Healthcare Conference
    • Fireside Chat Presentation on June 2, 2021 at 3:30 p.m. ET
  • The JMP Securities Life Sciences Conference
    • Fireside Chat Presentation on June 16, 2021 at 11:30 a.m. ET

A live webcast of the presentations may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcasts will be available on Concert’s website for two weeks following the presentations.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform® (deuterated chemical entity platform). Selective incorporation of deuterium into known molecules has the potential, on a case-by-case basis, to provide better pharmacokinetic or metabolic properties, thereby enhancing their clinical safety, tolerability or efficacy. Concert’s lead product candidate is in late-stage development for the treatment of alopecia areata, a serious autoimmune dermatological condition. Concert is also assessing a number of earlier-stage pipeline candidates. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Concert Pharmaceuticals, Inc.

NASDAQ:CNCE

Release Summary
In June, Concert will participate virtually in fireside chats at both the Jefferies and JMP Securities healthcare conferences.
Release Versions
$Cashtags

Contacts

Justine Koenigsberg
(781) 674-5284
ir@concertpharma.com

Social Media Profiles
More News From Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert maintains deuruxolitinib breakthrough therapy designation from FDA for the treatment of alopecia areata....

Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata

MUMBAI & LEXINGTON, Mass.--(BUSINESS WIRE)--Sun Pharma to acquire Concert Pharmaceuticals....

Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research

MELBOURNE, Australia--(BUSINESS WIRE)--The presentation includes new analyses on the effect of baseline severity and duration of current episode of hair loss on scalp hair regrowth....
Back to Newsroom